+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID03016819

Phase 3 Study of Oral Anlotinib AL3818 in Treating Adults with Advanced or Metastatic Alveolar Soft Part Sarcoma

Led by Advenchen Laboratories, LLC · Updated on 2026-02-25

325

Participants Needed

24

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of AL3818 anlotinib hydrochloride in treating metastatic or advanced alveolar soft part sarcoma ASPS, leiomyosarcoma LMS, and synovial sarcoma SS. This phase 3 study focuses on patients with ASPS receiving open-label AL3818, while those with LMS or SS are randomized to receive either AL3818 or IV dacarbazine. The study also includes pharmacokinetic and exposure-response analyses for AL3818. Participants with ASPS receive AL3818 orally at 12 mg once daily in 21-day cycles, with 14 days on treatment and 7 days off, continuing until disease progression or unacceptable side effects. For LMS and SS, participants are randomly assigned in a 21 ratio to either AL3818 or IV dacarbazine, with the option to switch to AL3818 if disease progresses on dacarbazine. The study also includes a subgroup assessing cardiac effects and drug interactions of catequentinib hydrochloride, related to AL3818. During the study, participants undergo regular assessments including imaging scans to measure tumor response using RECIST criteria, laboratory tests to monitor organ function, and electrocardiograms to evaluate heart activity. Researchers track outcomes such as objective response rate, progression-free survival, and duration of response over up to 48 months. Safety is closely monitored, and participants may continue treatment or switch therapies based on disease progression and tolerance. The total study duration varies by participant and includes detailed pharmacokinetic and cardiac safety evaluations.

CONDITIONS

Brief Title

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Research Team

S

Shiying Clinical Trial Manager

J

Judy Clinical Trial Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here